These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 18018758

  • 1. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications.
    Tarr PE, Telenti A.
    Antivir Ther; 2007; 12(7):999-1013. PubMed ID: 18018758
    [Abstract] [Full Text] [Related]

  • 2. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.
    Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A, Weber R, Ledergerber B, Telenti A, Tarr PE, Swiss HIV Cohort Study.
    Circ Cardiovasc Genet; 2009 Dec; 2(6):621-8. PubMed ID: 20031643
    [Abstract] [Full Text] [Related]

  • 3. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.
    Tarr PE, Taffé P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vernazza P, Bernasconi E, Darioli R, Rickenbach M, Ledergerber B, Telenti A, Swiss HIV Cohort Study.
    J Infect Dis; 2005 May 01; 191(9):1419-26. PubMed ID: 15809899
    [Abstract] [Full Text] [Related]

  • 4. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM, Lassalle R, Capeau J, Bach-Ngohou K, Nazih-Sanderson F, Rémy G, Reynes J, Ecobichon JL, Savès M, Raffi F, Aproco-Copilote Study Group.
    Antivir Ther; 2006 May 01; 11(3):361-70. PubMed ID: 16759053
    [Abstract] [Full Text] [Related]

  • 5. Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy.
    Nasi M, Guaraldi G, Orlando G, Durante C, Pinti M, Nemes E, Nardini G, Passarino G, Cocchi M, Esposito R, Mussini C, Cossarizza A.
    Clin Infect Dis; 2008 Oct 01; 47(7):962-8. PubMed ID: 18752438
    [Abstract] [Full Text] [Related]

  • 6. Lack of mutations in LMNA, its promoter region, and the cellular retinoic acid binding protein II (CRABP II) in HIV associated lipodystrophy.
    Behrens GM, Genschel J, Schmidt RE, Schmidt HH.
    Eur J Med Res; 2003 May 30; 8(5):221-5. PubMed ID: 12844477
    [Abstract] [Full Text] [Related]

  • 7. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
    Falutz J.
    Nat Clin Pract Endocrinol Metab; 2007 Sep 30; 3(9):651-61. PubMed ID: 17710086
    [Abstract] [Full Text] [Related]

  • 8. HIV lipodystrophy and its metabolic consequences: implications for clinical practice.
    Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS.
    Curr Med Res Opin; 2008 Mar 30; 24(3):609-24. PubMed ID: 18208641
    [Abstract] [Full Text] [Related]

  • 9. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV.
    Boehme RE, Cameron S.
    Antivir Ther; 2009 Mar 30; 14(8):1195-208. PubMed ID: 20032550
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-18 and interferon-gamma polymorphisms in Brazilian human immunodeficiency virus-1-infected patients presenting with lipodystrophy syndrome.
    Castelar L, Silva MM, Castelli EC, Deghaide NH, Mendes-Junior CT, Machado AA, Donadi EA, Fernandes AP.
    Tissue Antigens; 2010 Aug 30; 76(2):126-30. PubMed ID: 20331838
    [Abstract] [Full Text] [Related]

  • 11. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G, Toro GM.
    BMC Infect Dis; 2005 Oct 03; 5():80. PubMed ID: 16202141
    [Abstract] [Full Text] [Related]

  • 12. Beyond lipodystrophy: will toxicity issues ever outweigh the benefits of HAART?
    Vella S, Palmisano L.
    J HIV Ther; 2003 May 03; 8(2):27-8. PubMed ID: 15587479
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mitochondrial impact of human immunodeficiency virus and antiretrovirals on infected pediatric patients with or without lipodystrophy.
    Morén C, Noguera-Julian A, Rovira N, Corrales E, Garrabou G, Hernández S, Nicolás M, Tobías E, Cardellach F, Miró O, Fortuny C.
    Pediatr Infect Dis J; 2011 Nov 03; 30(11):992-5. PubMed ID: 21697766
    [Abstract] [Full Text] [Related]

  • 17. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F, Domingo P, Viladés C, Peraire J, Arnedo M, Alcamí J, Leal M, Villarroya F, Gatell JM.
    Expert Opin Drug Metab Toxicol; 2011 Nov 03; 7(11):1365-82. PubMed ID: 21999362
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA, Bryant BJ, AACC Pharmacogenomic Committee.
    Am J Pharmacogenomics; 2004 Nov 03; 4(3):141-50. PubMed ID: 15174895
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.